[go: up one dir, main page]

BR112012019050A8 - sais e polimorfos de 8-fluoro-2-{metilamino)metil]fenil}-1,3,4,5-tetra-hidro-6h-azepino[5,4,3cd]indol-6-ona. - Google Patents

sais e polimorfos de 8-fluoro-2-{metilamino)metil]fenil}-1,3,4,5-tetra-hidro-6h-azepino[5,4,3cd]indol-6-ona.

Info

Publication number
BR112012019050A8
BR112012019050A8 BR112012019050A BR112012019050A BR112012019050A8 BR 112012019050 A8 BR112012019050 A8 BR 112012019050A8 BR 112012019050 A BR112012019050 A BR 112012019050A BR 112012019050 A BR112012019050 A BR 112012019050A BR 112012019050 A8 BR112012019050 A8 BR 112012019050A8
Authority
BR
Brazil
Prior art keywords
methyl
azepino
tetrahydro
fluoro
polymorphs
Prior art date
Application number
BR112012019050A
Other languages
English (en)
Other versions
BR112012019050B1 (pt
BR112012019050A2 (pt
Inventor
Gillmore Adam
Michael Campeta Anthony
Kougoulos Eleftherios
Cameron Jones Matthew
Ann Basford Patricia
Walton Robert
Luthra Suman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43859823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012019050(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of BR112012019050A2 publication Critical patent/BR112012019050A2/pt
Publication of BR112012019050A8 publication Critical patent/BR112012019050A8/pt
Publication of BR112012019050B1 publication Critical patent/BR112012019050B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

sais e polimorfos de 8-fluoro-2{metil-amino)metil]fenil}-1,3,4,5-tetra-hidro-6h-azepino[5,4,3cd]in-dol-6-ona. a presente invenção refere-se a novas formas polimórficas de 8-fluoro-2-{4-[metilamino)metil}-1,3,4,5-tetra-hidro-6h-azepino[5,4,3-cd]indo-6-ona, e aos processos para sua preparação. tais formas polimórficas podem ser um componente de uma composição farmacêutica e podem ser usadas para tratar uma condição de doença mamífera mediada por atividade de poli(adp-ribose) polimerase incluindo a condição de doença tal como câncer.
BR112012019050-4A 2010-02-12 2011-02-10 Sal anidro de forma a do s-camsilato de 8-fluoro-2-{metilamino)metil]fenil}-1,3,4,5-tetra- hidro-6hazepino[5,4,3cd]indol-6-ona, composição e uso do mesmo BR112012019050B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30427710P 2010-02-12 2010-02-12
US61/304,277 2010-02-12
PCT/IB2011/050571 WO2011098971A1 (en) 2010-02-12 2011-02-10 Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

Publications (3)

Publication Number Publication Date
BR112012019050A2 BR112012019050A2 (pt) 2016-09-13
BR112012019050A8 true BR112012019050A8 (pt) 2017-12-26
BR112012019050B1 BR112012019050B1 (pt) 2021-12-21

Family

ID=43859823

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012019050-4A BR112012019050B1 (pt) 2010-02-12 2011-02-10 Sal anidro de forma a do s-camsilato de 8-fluoro-2-{metilamino)metil]fenil}-1,3,4,5-tetra- hidro-6hazepino[5,4,3cd]indol-6-ona, composição e uso do mesmo

Country Status (31)

Country Link
US (5) US8754072B2 (pt)
EP (4) EP3597651A1 (pt)
JP (6) JP5745283B2 (pt)
KR (2) KR102108226B1 (pt)
CN (2) CN104876937B (pt)
AR (2) AR080164A1 (pt)
AU (1) AU2011213944B2 (pt)
BR (1) BR112012019050B1 (pt)
CA (2) CA3024216C (pt)
CY (3) CY1118319T1 (pt)
DK (2) DK2534153T4 (pt)
ES (2) ES2753748T3 (pt)
FI (1) FI2534153T4 (pt)
HR (2) HRP20161742T4 (pt)
HU (3) HUE030969T4 (pt)
IL (1) IL220921B (pt)
LT (3) LT2534153T (pt)
LU (1) LUC00093I2 (pt)
MX (1) MX343383B (pt)
NL (1) NL300958I2 (pt)
NO (1) NO2018039I1 (pt)
NZ (1) NZ601445A (pt)
PL (2) PL3150610T3 (pt)
PT (2) PT3150610T (pt)
RS (2) RS55487B2 (pt)
RU (1) RU2570198C2 (pt)
SG (2) SG10201406805RA (pt)
SI (2) SI2534153T2 (pt)
SM (3) SMT201900634T1 (pt)
TW (1) TWI545123B (pt)
WO (1) WO2011098971A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3597651A1 (en) 2010-02-12 2020-01-22 Pfizer Inc Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
TW201516636A (zh) * 2013-10-22 2015-05-01 Hon Hai Prec Ind Co Ltd 電子裝置及其供電方法
EP3182975A4 (en) 2014-08-22 2018-04-18 Clovis Oncology, Inc. High dosage strength tablets of rucaparib
AU2017267768A1 (en) * 2016-05-16 2019-01-03 Gb001, Inc. Crystal of quinoline derivative
DE102016218772A1 (de) * 2016-09-28 2018-03-29 Bruker Biospin Gmbh Verbesserte Temperierung eines NMR-MAS-Rotors
HRP20241280T1 (hr) * 2017-01-24 2024-12-06 Assia Chemical Industries Ltd. Kruti oblici rukapariba i soli rukapariba
CN109651377B (zh) * 2017-10-12 2020-10-20 成都海创药业有限公司 一种治疗癌症的化合物及其用途
MX2020004545A (es) * 2017-11-03 2020-08-03 Sandoz Ag Sal cristralina de un inhibidor triciclico de poli(adp-ribosa)-polimerasa.
WO2019115000A1 (en) * 2017-12-15 2019-06-20 Advitech Advisory And Technologies Sa Process for the preparation of rucaparib and novel synthesis intermediates
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
CA3088858A1 (en) 2018-01-05 2019-07-11 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
US10442813B2 (en) 2018-01-30 2019-10-15 RK Pharma Solutions LLC Polymorphs of rucaparib camsylate and methods of making same
WO2019207596A1 (en) 2018-04-25 2019-10-31 Mylan Laboratories Limited Novel crystalline forms of rucaparib (s)-camsylate salt and rucaparib free base
WO2019207498A1 (en) * 2018-04-25 2019-10-31 Biophore India Pharmaceuticals Pvt. Ltd Solid forms of 8-fluoro-2-{4-[(methylamino)methyl] phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd] indol-6-one ((1s,4r)-7,7dimethyl-2-oxobicyclo [2.2.1] hept-1-yl) methanesulfonic acid salt (rucaparib camsylate) and the prerparation thereof
CN108743557A (zh) * 2018-06-27 2018-11-06 李莉 一种磷酸瑞卡帕布软胶囊及其制备方法
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
MA54091A (fr) 2018-10-30 2021-09-15 Repare Therapeutics Inc Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr
CN111217818A (zh) * 2018-11-27 2020-06-02 台耀化学股份有限公司 芦卡帕尼樟脑磺酸盐的结晶、及制备三环化合物、芦卡帕尼及其樟脑磺酸盐结晶的方法
WO2020113500A1 (zh) * 2018-12-06 2020-06-11 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
PE20220563A1 (es) 2019-07-10 2022-04-13 Cybrexa 2 Inc Conjugados peptidicos de citotoxinas como terapeuticos
MX2022000450A (es) 2019-07-10 2022-04-25 Cybrexa 3 Inc Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos.
CN111004244A (zh) * 2019-12-27 2020-04-14 重庆市碚圣医药科技股份有限公司 一种瑞卡帕布樟脑磺酸盐的合成方法
WO2021156140A1 (en) 2020-02-03 2021-08-12 Sandoz Ag Polymorph of rucaparib mesylate
BR112022021089A2 (pt) * 2020-04-24 2022-12-06 Astrazeneca Ab Formulações farmacêuticas
PT4143182T (pt) 2020-04-28 2025-03-13 Rhizen Pharmaceuticals Ag Novos compostos úteis como inibidores da poli(adp-ribose) polimerase (parp)
AU2021304826A1 (en) 2020-07-10 2023-02-02 The Regents Of The University Of Michigan GAS41 inhibitors and methods of use thereof
EP4182318A1 (en) 2020-07-14 2023-05-24 Assia Chemical Industries Ltd Solid state forms of rucaparib salts
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CN117321044A (zh) 2021-04-08 2023-12-29 理森制药股份公司 聚(adp-核糖)聚合酶抑制剂
US20250223295A1 (en) 2022-01-11 2025-07-10 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate
WO2023152754A1 (en) * 2022-02-08 2023-08-17 Sawant, Mohit Manikrao Crystalline form of rosuvastatin allyl ester
AU2022489881A1 (en) * 2022-11-30 2025-06-19 Ideaya Biosciences, Inc. 2-oxoquinazoline crystalline forms

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489011A (en) 1983-05-16 1984-12-18 Merrell Dow Pharmaceuticals Inc. Hypoglycemic N-(2-substituted-3-dialkylamino-2-propenylidene)-N-alkylalkanaminium camsylate salts
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
DE4125292A1 (de) * 1991-07-31 1993-02-04 Kali Chemie Pharma Gmbh 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
ES2153031T4 (es) 1995-04-20 2001-05-16 Pfizer Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
EP0780386B1 (en) 1995-12-20 2002-10-02 F. Hoffmann-La Roche Ag Matrix metalloprotease inhibitors
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
JP3195756B2 (ja) 1996-07-04 2001-08-06 公子 吉水 潤滑補助体
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ATE231148T1 (de) 1996-07-13 2003-02-15 Glaxo Group Ltd Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
ES2186908T3 (es) 1996-07-13 2003-05-16 Glaxo Group Ltd Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas.
TR199900066T2 (xx) 1996-07-18 1999-04-21 Pfizer Inc. Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri
SK21499A3 (en) 1996-08-23 2000-05-16 Pfizer Arylsulfonylamino hydroxamic acid derivatives
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
AU5131998A (en) 1997-01-06 1998-08-03 Pfizer Inc. Cyclic sulfone derivatives
IL131042A (en) 1997-02-03 2004-07-25 Pfizer Prod Inc Derivatives of arylsulfonamic acid hydroxyamic acid and medicinal preparations containing them
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
CA2280151C (en) 1997-02-11 2005-12-13 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
CA2289102A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
US5835420A (en) 1997-06-27 1998-11-10 Aplus Flash Technology, Inc. Node-precise voltage regulation for a MOS memory system
JP3448275B2 (ja) 1997-08-08 2003-09-22 ファイザー・プロダクツ・インク アリールオキシアリールスルホニルアミノヒドロキサム酸誘導体
ES2289791T3 (es) 1997-08-22 2008-02-01 Astrazeneca Ab Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
WO1999016755A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
SK6652000A3 (en) 1997-11-11 2002-05-09 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
JP4462654B2 (ja) 1998-03-26 2010-05-12 ソニー株式会社 映像素材選択装置及び映像素材選択方法
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
CN1250526C (zh) 1998-05-29 2006-04-12 苏根公司 吡咯取代的2－吲哚满酮蛋白激酶抑制剂
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
EP1004578B1 (en) 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
BR9916518A (pt) 1998-12-23 2002-01-29 Searle & Co Método para tratar ou prevenir um distúrbio de neoplasia em um mamìfero em necessidade de tal tratamento ou prevenção, e, combinação compreendendo um inibidor de ciclooxigenase-2 e um ou mais agentes anti-neoplásticos
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
ES2218110T3 (es) 1999-01-11 2004-11-16 Agouron Pharmaceuticals, Inc. Inhibidores triciclicos de poli(adp-ribosa)polimerasas.
KR100452491B1 (ko) 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
KR20040011751A (ko) 2002-07-30 2004-02-11 씨제이 주식회사 암로디핀의 유기산염
EP1575936A1 (en) † 2002-12-19 2005-09-21 Pfizer Products Inc. Complexes of e-2-methoxy-n-(3-{4- [3-methyl-4-(6-methyl- pyridin -3-yloxy)-phenylamino] -quinazolin-6-yl}-allyl)-acetamide, their method of production, and use
EP1611137A1 (en) 2003-03-31 2006-01-04 Pfizer Inc. Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
EP1660095B1 (en) 2003-07-25 2010-01-13 Cancer Research Technology Limited Tricyclic parp inhibitors
CN101384264B (zh) * 2004-09-22 2012-03-14 辉瑞大药厂 含有聚（adp-核糖）聚合酶抑制剂的治疗组合物
SI1794163T1 (sl) 2004-09-22 2010-04-30 Pfizer Postopek priprave inhibitorjev poli(ADP-riboza) polimeraz
CA2581200A1 (en) * 2004-09-22 2006-03-30 Pfizer Inc. Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
KR100853601B1 (ko) * 2004-09-22 2008-08-22 화이자 인코포레이티드 8-플루오로-2-｛4-[(메틸아미노)메틸]페닐｝-1,3,4,5-테트라하이드로-6Ｈ-아제피노[5,4,3-ｃｄ]인돌-6-온의포스페이트 염의 다형성 및 무정형 형태
GB0502509D0 (en) 2005-02-07 2005-03-16 Pfizer Ltd Novel salt form of a dopamine agonist
KR20180026580A (ko) * 2005-02-23 2018-03-12 테바 파마슈티컬 인더스트리즈 리미티드 함량 균일성이 개선된 라사길린 제형
RU2009103658A (ru) * 2006-07-05 2010-08-10 Тева Фармасьютикал Индастриес Лтд. (Il) Фармацевтические композиции мемантина
KR100843401B1 (ko) 2006-12-04 2008-07-04 씨제이제일제당 (주) 결정성 ｓ-(-)-암로디핀 캠실레이트 무수물 및 이의제조방법
DK2091910T3 (en) * 2006-12-06 2014-12-01 Conatus Pharmaceuticals Inc Crystalline forms of (3S) -3- [N- (N '- (2-tert-butylphenyl) oxamyl) alaninyl] amino-5- (2', 3 ', 5', 6'-tetrafluorophenoxy) -4-oxopentanoic acid
WO2008114114A2 (en) 2007-03-16 2008-09-25 Pfizer Products Inc. Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
EP2065385A1 (en) 2007-11-28 2009-06-03 Laboratorios SALVAT, S.A. Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
US20110053997A1 (en) * 2007-12-05 2011-03-03 Alexander Beliaev Salts and Crystal Forms
KR20090060674A (ko) 2007-12-10 2009-06-15 씨제이제일제당 (주) 결정형의 지프라시돈 술폰산염, 그 제조방법, 및 그것를포함하는 약제학적 조성물
US8436185B2 (en) 2008-01-08 2013-05-07 Merck Sharp & Dohme Corp. Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
US8494703B2 (en) 2009-01-17 2013-07-23 Boomerang Systems, Inc. Variable offset positioning antenna array for enhanced guidance of automated guided vehicles (AGVS)
EP3597651A1 (en) * 2010-02-12 2020-01-22 Pfizer Inc Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
US9539930B2 (en) 2011-09-23 2017-01-10 Gentex Corporation Systems and methods for rear view mirror displays
WO2013099476A1 (ja) 2011-12-26 2013-07-04 ウィンテックポリマー株式会社 ポリブチレンテレフタレート樹脂ペレット、及び当該ポリブチレンテレフタレート樹脂ペレットの製造方法
US9384339B2 (en) 2012-01-13 2016-07-05 Telecommunication Systems, Inc. Authenticating cloud computing enabling secure services
US9697529B2 (en) 2012-03-13 2017-07-04 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
KR101984831B1 (ko) 2013-01-31 2019-05-31 삼성전자 주식회사 반도체 패키지 및 그 제조 방법
CN103309115B (zh) 2013-05-30 2016-03-23 京东方科技集团股份有限公司 彩色电泳显示面板及其制造方法、显示装置
US9501163B2 (en) 2014-05-06 2016-11-22 Symbol Technologies, Llc Apparatus and method for activating a trigger mechanism
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys
JP6943759B2 (ja) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 シフト装置

Also Published As

Publication number Publication date
CY1122218T1 (el) 2020-11-25
PT3150610T (pt) 2019-11-11
BR112012019050B1 (pt) 2021-12-21
US20140243318A1 (en) 2014-08-28
US9861638B2 (en) 2018-01-09
HRP20191944T1 (hr) 2020-01-24
AR080164A1 (es) 2012-03-21
SMT201600462T1 (it) 2017-03-08
RS55487B1 (sr) 2017-04-28
LUC00093I2 (pt) 2019-12-24
CN102884066A (zh) 2013-01-16
JP2021107460A (ja) 2021-07-29
SI2534153T2 (sl) 2024-07-31
TW201144316A (en) 2011-12-16
EP2534153B1 (en) 2016-09-21
FI2534153T4 (fi) 2024-06-26
JP2015131858A (ja) 2015-07-23
SMT201900634T1 (it) 2020-01-14
KR20190026043A (ko) 2019-03-12
DK2534153T4 (da) 2024-06-03
LUC00093I1 (pt) 2018-11-15
LT3150610T (lt) 2019-11-11
CA3024216C (en) 2021-03-30
JP2020050671A (ja) 2020-04-02
SI2534153T1 (sl) 2017-01-31
MX2012008911A (es) 2012-08-15
RS59494B1 (sr) 2019-12-31
KR20120127495A (ko) 2012-11-21
PL3150610T3 (pl) 2020-02-28
US8754072B2 (en) 2014-06-17
CA3024216A1 (en) 2011-08-18
DK3150610T3 (da) 2019-11-04
RU2570198C2 (ru) 2015-12-10
CY1118319T1 (el) 2017-06-28
EP3597651A1 (en) 2020-01-22
SG182533A1 (en) 2012-08-30
HUE047248T2 (hu) 2020-04-28
ES2753748T3 (es) 2020-04-14
MX343383B (es) 2016-11-03
TWI545123B (zh) 2016-08-11
JP5745283B2 (ja) 2015-07-08
BR112012019050A2 (pt) 2016-09-13
WO2011098971A1 (en) 2011-08-18
LTC2534153I2 (lt) 2021-03-10
HUE030969T2 (en) 2017-06-28
US20200000821A1 (en) 2020-01-02
DK2534153T3 (en) 2017-01-09
SMT201600462B (it) 2017-03-08
JP6640931B2 (ja) 2020-02-05
CA2787881A1 (en) 2011-08-18
JP6013551B2 (ja) 2016-10-25
EP2534153A1 (en) 2012-12-19
NZ601445A (en) 2014-08-29
JP2016216507A (ja) 2016-12-22
CN102884066B (zh) 2015-01-07
CA2787881C (en) 2019-01-08
CN104876937B (zh) 2017-07-28
JP2018199679A (ja) 2018-12-20
AU2011213944A1 (en) 2012-08-09
EP2534153B2 (en) 2024-05-22
HK1176617A1 (zh) 2013-08-02
US9045487B2 (en) 2015-06-02
PL2534153T3 (pl) 2017-08-31
KR102108226B1 (ko) 2020-05-08
AR109356A2 (es) 2018-11-21
EP3150610A1 (en) 2017-04-05
RS55487B2 (sr) 2024-06-28
LT2534153T (lt) 2016-12-12
CY2018031I2 (el) 2019-11-27
SG10201406805RA (en) 2014-11-27
NO2018039I1 (no) 2018-11-15
JP6371350B2 (ja) 2018-08-08
IL220921B (en) 2020-03-31
HUE030969T4 (hu) 2024-11-28
AU2011213944B2 (en) 2014-10-02
US10278974B2 (en) 2019-05-07
ES2607806T5 (es) 2024-10-07
SI3150610T1 (sl) 2019-12-31
CY2018031I1 (el) 2019-11-27
EP3150610B1 (en) 2019-07-31
CN104876937A (zh) 2015-09-02
LTPA2018517I1 (lt) 2018-12-10
NL300958I2 (nl) 2018-12-19
US20150238504A1 (en) 2015-08-27
EP4166558A1 (en) 2023-04-19
HUS1800046I1 (hu) 2018-12-28
ES2607806T3 (es) 2017-04-04
US20120302550A1 (en) 2012-11-29
US20180092925A1 (en) 2018-04-05
RU2012138892A (ru) 2014-03-20
HRP20161742T1 (hr) 2017-02-24
HRP20161742T4 (hr) 2024-07-05
PL2534153T5 (pl) 2024-11-18
JP2011168587A (ja) 2011-09-01
PT2534153T (pt) 2016-12-27

Similar Documents

Publication Publication Date Title
BR112012019050A8 (pt) sais e polimorfos de 8-fluoro-2-{metilamino)metil]fenil}-1,3,4,5-tetra-hidro-6h-azepino[5,4,3cd]indol-6-ona.
BR112015029972A2 (pt) composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença, conjunto e utilização de um composto
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
PE20180318A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
CY1116439T1 (el) Τριαζολοπυριδινες
MX382599B (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina.
DOP2010000320A (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
CR20110452A (es) Inhibidores de la poli (adp-ribosa) polimerasa (parp)
CU20100062A7 (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteínas quinasas b
CY1116958T1 (el) Υποκατεστημενες τριαζολοπυριδινες και η χρηση τους ως ττκ αναστολεις
BRPI0909040A8 (pt) Derivados de azetidina e ciclobutano, seus usos, e composição
MX378354B (es) Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
CU20160096A7 (es) Formas sólidas cristalinas 7 y 8 de (s)-isopropil 2-((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(fenoxi)fosforilamino)propanoato de metilo (sofosbuvir)
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
BR112018011929A2 (pt) composto, composição farmacêutica, métodos para tratamento da infecção viral da hepatite c, de carcinoma basocelular, de ceratose actínica, da infecção viral de papiloma genital e da infecção viral de hepatite c, processo para preparação de um composto, e, uso de um composto
DOP2015000289A (es) Compuestos de 3,4-dihidroisoquinolin-2(1h)-ilo
BRPI0516766A (pt) formas polimórficas e amorfas do sal de fosfato de 8-flúor-2{4-[(metilamino)metil]fenil}-1,3,4,5-tetraidro- 6h-azepino[5,4,3-cd]indol-6-ona, composição farmacêutica, formas de dosagens e respectivo uso
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
BR112017028604A2 (pt) forma cristalina de base livre de lorlatinibe
MX2014005342A (es) Inhibidores del virus de la hepatitis c.
CL2013003056A1 (es) Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas.
CL2012003212A1 (es) Formas cristalinas i y ii de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida monohidratado; procedimientos de preparacion; composicion farmaceutica; su procedimiento de preparacion; y su uso para el tratamiento de trastornos tales como trastorno por deficit de atencion y enfermedad de parkinson.
CL2013000730A1 (es) Proceso para preparar compuestos derivados de dihidropteridinonas, moduladores de la quinasa tipo polo plk-1, útiles para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes; procesos de preparacion de compuestos intermediarios.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/02/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2761 DE 05/12/2023 POR TER SIDO INDEVIDA.